Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis

Arthritis and Rheumatism

Volumn 63, Issue 5, 2011, Pages 1452-1458

  Vojinovic, Jelena ^a   Damjanov, Nemanja ^b   D'Urzo, Carmine ^c   Furlan, Antonio ^d   Susic, Gordana ^b   Pasic, Srdjan ^e   Iagaru, Nicola ^f   Stefan, Mariana ^g   Dinarello, Charles A ^g  

^a University Clinical Center Nis   (Serbia)

^b INSTITUTE OF RHEUMATOLOGY   (Serbia)

^c Italfarmaco SpA   (Italy)

^d UNIVERSITY OF COLORADO   (United States)

^e Mother and Child Health Care Institute   (Serbia)

^f Institute of Mother and Child Protection Alfred Rusescu   (Romania)

^g Maria Sklodowska Curie Children's Emergency Hospital   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

GIVINOSTAT; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QT PROLONGATION; SCHOOL CHILD; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; FEMALE; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INTENTION TO TREAT ANALYSIS; MALE; TREATMENT OUTCOME;

EID: 79955552937     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30238     Document Type: Article

References (15)

1. Jungel A, Ospelt C, Gay S,. What can we learn from epigenetics in the year 2009? Curr Opin Rheumatol 2010; 22: 284-92.
2. Halili MA, Andrews MR, Sweet MJ, Fairlie DP,. Histone deacetylase inhibitors in inflammatory disease. Curr Top Med Chem 2009; 9: 309-19.
3. Faraco G, Pittelli M, Cavone L, Fossati S, Porcu M, Mascagni P, et al. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol Dis 2009; 36: 269-79.
4. Leoni F, Fossati G, Lewis EC, Lee JK, Porro G, Pagani P, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med 2005; 11: 1-15.
5. Brogdon JL, Xu Y, Szabo SJ, An S, Buxton F, Cohen D, et al. Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function. Blood 2007; 109: 1123-30. (Pubitemid 46220659)
6. Grabiec AM, Krausz S, de Jager W, Burakowski T, Groot D, Sanders ME, et al. Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J Immunol 2010; 184: 2718-28.
7. Vastert SJ, Kuis W, Grom AA,. Systemic JIA: new developments in the understanding of the pathophysiology and therapy. Best Pract Res Clin Rheumatol 2009; 23: 655-64.
8. Gattorno M, Piccini A, Lasiglie D, Tassi S, Brisca G, Carta S, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2008; 58: 1505-15. (Pubitemid 351705940)
9. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2. (Pubitemid 38160763)
10. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9. (Pubitemid 27430130)
11. Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol 2001; 19 Suppl 23: S1-9. (Pubitemid 33730178)
12. Oldoni T, Furlan A, Monznani V, Dinarello CA,. Decreased whole blood cytokine production during a phase I trial of the histone deacetylase inhibitor ITF2357 [abstract]. Cytokine 2009; 48: 120.
13. Verbsky JW, White AJ,. Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis. J Rheumatol 2004; 31: 2071-5. (Pubitemid 39336738)
14. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006. (Pubitemid 351389534)
15. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266-73.